PHP8 BENEFICIARY CHOICE IN MEDICARE PART D

PHP10 COST CONSEQUENCE ANALYSIS OF PRESCRIPTION DRUG LABEL CHANGES
Zargarzadeh AH, Law AV Western University of Health Sciences, Pomona, CA, USA OBJECTIVES: According to a mandate, all California pharmacies will be changing to a new "patient centered "prescription label beginning January 2011. An increase in label size may be needed to comply with possible additional information/format changes that are being considered. This cost consequence study explored the impact of label changes to California pharmacies and projected to all US pharmacies. METHODS: A cost model was built based on input from 3 experts. It included: 1) continuing costs: bottle, cap or closure, label (dual web sheet paper vs. thermal roll, paper used, glue used), and 2) One-time costs: software program, additional storage area and staff training. Average additional costs for increasing bottle size from 13 dram to 30 dram, increasing label size and added adhesive was estimated to be 10.5 cents. A literature search conducted to estimate consequence of label change identified only two articles that addressed the impact of a new commercial label on health outcomes and medication safety. RESULTS: The additional costs to pharmacies for the new label would be close to $34 million ($372M for US) assuming 324 million prescriptions are filled by retail and mail order pharmacies annually in California (3.54 billion for US). On average, each of 6000 California pharmacies will incur additional costs of $5700 dollars each year. Software changes were assumed to be zero cost. Additional storage and employee training were dealt with differently by each pharmacy hence were used as parameters for a sensitivity analysis. The two studies on consequence did not show any significant difference in impact on outcomes between using the new label and a traditional label. CONCLUSIONS: Additional costs of label change per pharmacy may not be considered significant; however these costs could be transferred to patients as pharmacies are already experiencing financial constraints.
PHP12 THE RELATIONSHIP OF RESEARCH AND DEVELOPMENT ACTIVITY WITH U.S. MEDICAL DRUG SHORTAGES
Stino M, McGhan WF University of the Sciences in Philadelphia, Philadelphia, PA, USA OBJECTIVES: In an earlier study, we explored the characteristics of the medical drugs and devices in short supply on or before June 1, 2009. In this study, we looked at the internal characteristics of the individual manufacturers for those drugs. In addition, we examined the possible association for firms with significant research and development (R&D) operations and the number and average length of shortages.
METHODS:
We assembled an expert panel to determine the R&D status of these firms based on whether or not their primary mission was to develop novel drugs. We conducted statistical analyses to test several null hypotheses: 1) that there is no association between a firm's R&D activity and the number of drugs in short supply for which it is listed; 2) that there is no association between a firm's R&D activity and the average length of its shortages; 3) that there is no difference between firms with significant R&D operations and other firms in regard to the number of shortages for which they are listed; and 4) that there is no difference between firms with significant R&D operations and other firms in regard to the average duration of their shortages. RESULTS: We failed to reject the null hypotheses for overall, active, and resolved shortages, except in one case. We found that there was no significance in most of these associations except in the relationship between a firm's R&D status and the length of its resolved shortages. CONCLUSIONS: Based on this data, these results suggest that firms classified as being research-intensive did not have significantly more drugs in short supply or longer durations for current and overall shortages. Firms focused on R&D had longer resolved shortages. We intend to continue investigating other manufacturer characteristics and their possible association with shortages. . MCBS is nationally representative survey of elderly and disabled individuals. The survey contains detailed information on prescription drug coverage, prescription drug utilization, and other sociodemographic, economic variables. The sample was limited to those age 65-85 years with complete year of data, either uninsured or who had private coverage. Prescription drug coverage was calculated for each month, if respondent had coverage for at least 6-months they were assumed to be privately insured. We estimate the likelihood of being uninsured using pre Medicare part D data from [2000] [2001] [2002] [2003] 
PHP13 MEDICARE PART D AND ITS IMPACT ON PRESCRIPTION DRUG USE
PHP14 ACCESS WITH EVIDENCE DEVELOPMENT SCHEMES: A FRAMEWORK FOR THEIR DESIGN AND EVALUATION
Stafinski T 1 , McCabe C 2 , Menon D 1 1 University of Alberta, Edmonton, AB, Canada, 2 University of Leeds, Leeds, West Yorkshire, UK OBJECTIVES: In recent years, efforts to balance access to promising, new technologies with the need to ensure effective and efficient use of limited health care resources have focussed on the adoption of various forms of conditional coverage arrangements, collectively referred to as Access with Evidence Development (AED) schemes. While such arrangements continue to attract interest, concerns over 'value for money' have also been raised, since they often require considerable, committed resources for implementation. This project aimed to develop a framework for guiding the design of future AED schemes and apply this framework to the evaluation of existing AED schemes. METHODS: An international workshop involving researchers and decision-makers with experience designing and implementing AED schemes was held. Presentations comprising case studies from Australia, Canada, the UK, and the US were used to highlight issues/challenges and lessons learnt. They were followed by discussions around the strengths/weaknesses and resource requirements of such schemes. Based
